1. 3-Deoxysappanone B has vasorelaxation effects, it can mediate endothelium- independent vasodilator action in rat thoracic aortic rings.
1. Pachyaximine A possesses significant antibacterial activity against Escherichia coli, Staphylococcus aureus, Corynebacterium diphtheriae and Corynebacterium pyrogenes.
2. (-)-Pachyaximine A demonstrates significant activity as antiestrogen binding site (AEBS)-inhibitory agents, and potentiates significantly the antiestrogenic effect mediated by tamoxifen in cultured Ishikawa cells.
1. Axillaridine shows significant activity as antiestrogen binding site-inhibitory agents.
2. The complexation of AChE with Axillaridine-A, results in the reduction of gorge size due to interaction between the ligand and the active site residues.
1. 6,8-Diprenylorobol possesses weaker anti-H. pylori activity, it may be a useful chemopreventive agent for peptic ulcer or gastric cancer in H. pylori-infected individuals.
2. 6,8-Diprenylorobol shows anti-estrogenic activity comparable to that of 4-hydroxytamoxifen, a typical estrogen receptor (ER) antagonist.
3. 6,8-Diprenylorobol shows promising cytotoxic effects toward HL-60 cells (IC50 4.3 ± 0.7 to 18.0 ± 1.7 uM).
4. 6,8-Diprenylorobol has antioxidant activity, it can reduce A2E photooxidation in a dose dependent manner.
5. 6,8-Diprenylorobol is evaluated against the AIDS-related opportunistic fungal pathogens, Candida albicans and Cryptococcus neoformans.
6. 6,8-Diprenylorobol can protect against 6-OHDA-induced neurotoxicity by enhancing the ubiquitin/proteasome-dependent degradation of α-synuclein and synphilin-1, suggesting that it may be a possible candidate for the treatment of neurodegenerative diseases.
1. Tracheloside significantly decreases the activity of alkaline phosphatase (AP), an estrogen-inducible marker enzyme, with an IC(50) value of 0.31 microg/ml, a level of inhibition comparable to that of tamoxifen (IC(50) = 0.43 microg/ml).